The FDA’s ODAC sought to determine whether cilta-cel has a favorable benefit-risk profile for patients with multiple myeloma. The FDA’s ODAC unanimously voted that the potential benefits of cilta-cel outweigh its risks for its proposed indication in patients with multiple myeloma.
The FDA’s ODAC sought to determine whether cilta-cel has a favorable benefit-risk profile for patients with multiple myeloma. The FDA’s ODAC unanimously voted that the potential benefits of cilta-cel outweigh its risks for its proposed indication in patients with multiple myeloma.
FDA approves earlier use of Carvykti CAR-T for multiple myeloma healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Tucson Weekly: Son Of A Gun (May 13 - May 19, 1999) tucsonweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tucsonweekly.com Daily Mail and Mail on Sunday newspapers.